RYR2 Antibody

What is RYR2 and what is its primary function in cellular physiology?

RYR2 (Ryanodine Receptor 2) is a calcium release channel primarily expressed in cardiac muscle, with significant presence also in brain tissue (particularly cerebellum and hippocampus) and placenta. It functions as a critical component of the calcium-induced calcium release (CICR) mechanism, providing communication between transverse-tubules and sarcoplasmic reticulum. As an intracellular calcium channel, RYR2 regulates cytosolic calcium, which acts as a key second messenger in multiple cellular pathways including muscle contraction, synaptic transmission, hormonal secretion, and cell growth . The protein has a calculated molecular weight of approximately 565 kDa, making it one of the largest ion channels identified .

How do I select the appropriate RYR2 antibody for my specific research application?

Selection should be based on multiple factors:

• Experimental application compatibility: Verify the antibody has been validated for your specific technique (WB, IHC, IF/ICC)

• Species reactivity: Ensure reactivity with your experimental model (human, mouse, rat, or other species)

• Epitope location: Consider whether the epitope is in the N-terminus or C-terminus, which can be crucial when studying truncation variants or mutations

• Validation evidence: Look for published literature using the antibody or validation data from manufacturers

For example, the Proteintech antibody (19765-1-AP) targets RYR2 in multiple applications (WB, IHC, IF/ICC, IF-P, ELISA) and shows reactivity with human, mouse, and rat samples . For Western blot analysis of RYR2 variants, researchers have successfully used combinations of antibodies targeting different epitopes, such as ARP106/1 (reacting to the far C-terminus, aa 4957-4967) and sc-376507 (reacting to the N-terminus) .

What are the optimal storage conditions for maintaining RYR2 antibody activity?

Most RYR2 antibodies should be stored at -20°C in their appropriate buffer. For instance, the Proteintech RYR2 antibody (19765-1-AP) is stored in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . This preparation remains stable for one year after shipment when properly stored. Importantly, with this formulation, aliquoting is unnecessary for -20°C storage. Some preparations (20μl sizes) may contain 0.1% BSA as a stabilizer . To maintain antibody integrity, avoid repeated freeze-thaw cycles and exposure to light.

What are the recommended dilutions for RYR2 antibodies across different experimental applications?

Based on validated protocols, the following dilution ranges apply:

It is essential to titrate these antibodies in each specific experimental system to obtain optimal results, particularly when working with different tissue types or experimental conditions .

What are the methodological considerations for using RYR2 antibodies in immunohistochemistry of cardiac tissue?

When performing immunohistochemistry on cardiac tissue:

• Tissue preparation: For paraffin-embedded sections of myocardium, optimal results have been achieved at antibody dilutions around 1:50

• Antigen retrieval: TE buffer at pH 9.0 is recommended, although citrate buffer at pH 6.0 may be used as an alternative

• Background reduction: Be aware that cardiomyocytes show specific staining, while smooth muscle cells in artery walls are typically negative, providing an internal control for specificity

• Counterstaining: Hematoxylin provides excellent contrast as a counterstain for chromogenic detection systems

• Controls: Include controls preincubated with RYR2 blocking peptide to confirm specificity

Immunohistochemical staining of rat myocardium using anti-RYR2 antibody (1:50) demonstrates specific localization to cardiomyocytes while smooth muscle cells in artery walls remain negative, providing confirmation of specificity .

How can I validate the specificity of RYR2 antibodies for Western blot applications?

To validate RYR2 antibody specificity for Western blot:

• Blocking peptide competition: Pre-incubate the antibody with a specific RYR2 blocking peptide (such as BLP-RR002) before application to membranes

• Multiple antibody approach: Use antibodies targeting different epitopes of RYR2 to confirm consistent detection pattern

• Known positive controls: Include rat or mouse heart tissue lysates as positive controls (previously validated to express RYR2)

• Loading controls: Include appropriate loading controls to normalize protein expression

• RYR2 knockdown/knockout: If available, include samples with confirmed RYR2 knockdown or knockout

• Band size verification: Confirm detection at the expected molecular weight (approximately 565 kDa)

Western blot analysis of rat heart membranes using anti-RYR2 antibody (1:200) shows specific detection of the protein, with confirmation of specificity demonstrated by signal abolishment when the antibody is preincubated with RYR2 blocking peptide .

How does RYR2 expression differ across tissue types, and what implications does this have for antibody detection?

RYR2 exhibits differential expression across tissues:

In mouse cerebellum, immunohistochemical staining reveals the highest RYR2 expression in the molecular layer with additional expression in Purkinje cell soma. This localization can be confirmed by co-staining with parvalbumin (a marker for Purkinje cells) and visualizing the overlap between RYR2 (green fluorescence) and parvalbumin (red fluorescence) . The differential expression pattern requires optimization of antibody concentrations for each tissue type and consideration of appropriate positive and negative controls.

What methodological approaches are recommended for studying RYR2 expression in neuronal tissues?

For neuronal tissues, consider these methodological approaches:

• Frozen section preparation: For mouse cerebellum, frozen sections have yielded excellent results with anti-RYR2 antibody at 1:100 dilution using immunofluorescence

• Co-localization studies: Pair RYR2 staining with neuronal markers (e.g., parvalbumin for Purkinje cells) to confirm cell-type specific expression

• Counterstaining: DAPI works effectively as a nuclear counterstain in neuronal tissues

• Primary neuronal cultures: For hippocampal neurons, a 1:300 dilution has been validated for detecting endogenous RYR2

• Confocal microscopy: Required for precise subcellular localization, particularly for dendritic tree visualization

• Antigen retrieval optimization: May require different conditions than cardiac tissue

In mouse cerebellum, anti-RYR2 antibody (1:100) has successfully demonstrated that RYR2 is localized both in the area surrounding the dendritic tree and in the soma of Purkinje cells, with highest expression in the molecular layer .

How can I troubleshoot weak or absent RYR2 signal in Western blot experiments?

When facing weak or absent RYR2 signals in Western blot:

• Sample preparation: Ensure proper membrane enrichment as RYR2 is a membrane-bound protein; use specialized lysis buffers containing appropriate detergents

• Protein degradation: Include multiple protease inhibitors in all buffers due to RYR2's large size (565 kDa) making it susceptible to degradation

• Transfer efficiency: Use transfer methods optimized for very large proteins (e.g., extend transfer time or use specialized transfer systems)

• Antibody concentration: Consider using a more concentrated antibody solution (1:1000 instead of 1:6000)

• Detection system: Employ high-sensitivity detection systems for large proteins

• Gel percentage: Use low percentage gels (4-6%) to allow proper resolution of this high molecular weight protein

• Positive control: Always include a known positive control (heart tissue) to verify experimental conditions

If conventional troubleshooting fails, consider using alternative antibodies targeting different epitopes, as some regions may be masked by protein folding or post-translational modifications. For example, combining antibodies targeting the N-terminus and C-terminus has proven effective in studying RYR2 variants .

What are the potential causes and solutions for non-specific staining in RYR2 immunohistochemistry?

Non-specific staining may result from:

• Antibody concentration: Too high concentration can lead to non-specific binding; titrate the antibody to find optimal dilution (start with manufacturer recommendations, e.g., 1:100-1:400 for IHC)

• Inadequate blocking: Increase blocking time or concentration, or use alternative blocking reagents specific to tissue type

• Antigen retrieval issues: Optimize antigen retrieval method; for RYR2, TE buffer pH 9.0 is recommended, with citrate buffer pH 6.0 as an alternative

• Endogenous enzyme activity: Properly quench endogenous peroxidase or phosphatase activity

• Cross-reactivity: Verify antibody specificity using blocking peptides; RYR2 antibodies preincubated with specific blocking peptides (e.g., BLP-RR002) should show no staining

• Secondary antibody issues: Test secondary antibody alone to check for non-specific binding

• Tissue fixation artifacts: Optimize fixation time and conditions for specific tissue types

Include proper controls in each experiment, including tissue known to be negative for RYR2 (smooth muscle cells in arterial walls can serve as internal negative controls in cardiac sections) .

How can RYR2 antibodies be utilized to study nonsense variants and their effects on protein expression?

For studying nonsense variants in RYR2:

• Epitope-specific antibody selection: Use antibodies targeting epitopes both proximal and distal to the truncation site to determine if truncated protein is expressed

• Quantitative analysis: Calculate expression ratios between antibodies targeting different regions to estimate the relative abundance of truncated versus full-length protein

• Allele-specific detection: Combine with genetic strategies (e.g., allele-specific PCR) to distinguish expression from mutant versus wild-type alleles

• Cell models: Use patient-derived or genetically modified hiPSC-cardiomyocytes to study variant effects

In a study of the p.(Arg4790Ter) nonsense variant, researchers successfully used two antibodies with different epitope locations: ARP106/1 (targeting the far C-terminus, aa 4957-4967, distal to the variant) and sc-376507 (targeting the N-terminus, common to both mutant and wild-type RYR2). The ratio of expression from these antibodies in patient-derived hiPSC-cardiomyocytes compared to control cells provided insight into the presence and abundance of the truncated protein .

What methodological approaches can be used to study RYR2 calcium handling defects in human disease models?

Advanced approaches for studying RYR2 calcium handling include:

• Human iPSC-derived cardiomyocytes: Patient-specific or gene-edited models allow study of RYR2 variants in human cellular context

• Calcium imaging techniques: Combine RYR2 immunostaining with calcium indicators (Fluo-4, GCaMP) to correlate protein localization with functional calcium handling

• Super-resolution microscopy: Techniques like STORM or STED provide nanoscale visualization of RYR2 clustering and organization

• Allele-specific knockdown: Use shRNA targeting specific alleles (e.g., shRNA_11) to selectively reduce mutant RYR2 expression and assess functional consequences

• Electrophysiological recording: Patch-clamp techniques combined with RYR2 immunostaining to correlate structure with function

• Pharmacological manipulation: Test compounds that modify RYR2 function (stabilizers, inhibitors) to assess therapeutic potential

Researchers studying RYR2 nonsense variants successfully employed allele-specific shRNAs targeting the mutant allele, as verified by RT-PCR using primers based on the rs684923 SNP in RYR2. The shRNA_11 construct (with mutation recognition site at position 11 from the 5' end) significantly reduced mutant allele expression while increasing the wild-type/mutant expression ratio .

How can researchers effectively combine genetic and protein-level analyses when studying RYR2 variants in patient samples?

To effectively combine genetic and protein analyses:

• Coordinated sampling: Ensure tissue samples for protein analysis correspond to subjects with complete genetic characterization

• Allele-specific protein detection:

  • Use SNPs in linkage disequilibrium with the variant to track allele-specific expression

  • Design antibodies specifically recognizing common variants if possible

  • Employ mass spectrometry for peptide-level detection of specific variants

• Quantitative assessment: Use digital PCR and quantitative Western blotting to determine the ratio of wild-type to variant mRNA and protein

• Family studies: Analyze samples from family members to establish segregation patterns at both genetic and protein levels

• Functional correlation: Correlate protein expression patterns with clinical phenotypes and functional measurements

• Cell models: Generate isogenic cell lines differing only in the RYR2 variant to control for genetic background

In one research example, segregation studies on family members identified that the T allele of the rs684923 SNP segregated with a nonsense variant, allowing researchers to use this as a marker to reflect expression of the mutant allele specifically. This approach enabled precise tracking of mutant allele expression in response to targeted therapeutic interventions .

What are the emerging applications of RYR2 antibodies in single-cell analysis technologies?

Emerging single-cell applications include:

• Single-cell proteomics: Using RYR2 antibodies in mass cytometry (CyTOF) or single-cell Western blotting to analyze protein expression heterogeneity

• Spatial transcriptomics integration: Combining RYR2 immunohistochemistry with spatial transcriptomics to correlate protein localization with gene expression patterns

• Live-cell imaging: Using fluorescently-tagged antibody fragments to track RYR2 dynamics in living cells

• Nanobody development: Creating small antibody fragments for improved penetration and resolution in complex tissues

• Microfluidic applications: Integrating RYR2 antibodies into microfluidic platforms for automated single-cell analysis of cardiomyocytes

• Antibody-based cell sorting: Using RYR2 surface epitopes to isolate specific cardiac cell populations

These emerging technologies enable researchers to address previously intractable questions about cell-to-cell variability in RYR2 expression and function, potentially revealing subpopulations with distinct calcium handling properties relevant to cardiac disease mechanisms.

How should researchers approach conflicting RYR2 antibody results across different experimental platforms?

When facing conflicting results:

• Antibody validation hierarchy: Prioritize results from antibodies with the most rigorous validation (knockout controls, multiple application verification)

• Epitope availability considerations: Different experimental conditions may affect epitope accessibility; consider using multiple antibodies targeting different regions

• Cross-platform optimization: Systematically adjust protocols for each platform rather than using identical conditions

• Quantitative assessment: Implement quantitative measurements where possible to objectively compare results across platforms

• Standardization approaches: Include consistent positive and negative controls across all platforms to enable direct comparison

• Integrated data analysis: Combine data from multiple antibodies and techniques to develop a consensus model of RYR2 expression and function

A methodical approach to resolving conflicts includes validation experiments specifically designed to test hypotheses about why the conflicts occur, rather than simply declaring one result "correct" and others "artifacts."

What statistical approaches are recommended for analyzing RYR2 expression data in heterogeneous tissue samples?

For heterogeneous tissues:

• Spatial statistics: Apply spatial statistical methods to account for regional variation in RYR2 expression

• Multivariate analysis: Use principal component analysis or other multivariate approaches to identify patterns across multiple markers

• Mixed-effects modeling: Account for within-sample and between-sample variability using mixed-effects statistical models

• Bayesian approaches: Implement Bayesian statistics to incorporate prior knowledge about expected RYR2 expression patterns

• Machine learning classification: Train algorithms to identify and quantify cell types based on RYR2 and other marker expression

• Bootstrapping methods: Use resampling approaches to generate confidence intervals for expression estimates in heterogeneous samples

These advanced statistical approaches help researchers move beyond simple mean comparisons to capture the biological complexity of RYR2 expression in tissues containing multiple cell types with varying expression levels.